Primary Sclerosing Cholangitis News and Research

RSS

Garvan research reveals hidden inflammation behind high colon cancer risk

New research from the Garvan Institute of Medical Research has revealed for the first time that two closely related bowel diseases, currently treated in the same way, are fundamentally different.

22 Sep 2026

Gut bacterial metabolite linked to inflammation in liver disease

Researchers have identified a link between specific activities in gut bacteria and the liver disease PSC.

4 Sep 2026

Gut bacterial molecule discovered to drive serious bile duct disease

Researchers at the University of Oslo and Oslo University Hospital have, together with international collaborators, discovered that a small molecule made exclusively by gut bacteria can actively drive disease in the bile ducts and worsen primary sclerosing cholangitis (PSC), a serious liver and bile duct disease.

4 Sep 2026

PCORI funding awarded to study symptom management for rare cholestatic liver diseases

The Patient-Centered Outcomes Research Institute (PCORI) has announced a $13 million funding award to the University of North Carolina at Chapel Hill over five years to study innovative symptom management interventions for patients with rare cholestatic liver diseases.

1 Sep 2026

Optimized extended PCLS culture system extends tissue viability up to two weeks

Precision-cut liver slice (PCLS) technology has long been regarded as a promising ex vivo platform because it preserves the native multicellular architecture of liver tissue.

22 May 2026

Recent advancements in the development of models to study primary sclerosing cholangitis

Primary sclerosing cholangitis (PSC) is a rare non-communicable disorder that affects the liver. Chronic inflammation in and around the bile duct is followed by the development of fibrotic obstructions within the duct, causing bile to accumulate within the liver.

19 May 2026

Molecular test shows high sensitivity in detecting bile duct cancer

When patients develop a narrowing or blockage in the bile ducts – the tubes connecting the liver, gallbladder and intestines – physicians must determine whether the cause is cancer or a benign condition.

27 Mar 2026

Expert guidance on fecal microbiota transplantation in liver disease

The gut microbiota plays a crucial role in maintaining host health and liver function. Fecal microbiota transplantation (FMT), an emerging therapeutic modality, has demonstrated promising potential in the treatment of chronic liver diseases.

22 Jan 2026

Myosteatosis: An emerging predictor of outcomes in chronic liver disease

Myosteatosis, the pathological infiltration of fat into skeletal muscle, is increasingly recognized as a key predictor of poor clinical outcomes across a spectrum of liver diseases.

22 Jan 2026

Asian IBD patients show lower PSC prevalence and better clinical outcomes

Primary sclerosing cholangitis (PSC) is a chronic, progressive inflammatory disease characterized by fibrosis and bile duct stricturing, which ultimately leads to cirrhosis and liver failure. PSC is strongly associated with both types of inflammatory bowel disease (IBD), namely, ulcerative colitis and Crohn's disease.

2 Dec 2025

Blood group A linked to a higher risk of primary biliary cholangitis

Findings indicate blood group A elevates the risk of primary biliary cholangitis, suggesting ABO group analysis could aid in autoimmune liver disease diagnosis.

19 Nov 2025

Semi-synthetic bile acid could be a promising therapeutic option for TH17-mediated intestinal diseases

A research team from the Medical University of Vienna has made further progress in the treatment of intestinal inflammation.

14 Mar 2025

Older Americans find purpose and well-being in work, despite health barriers

Research shows older adults working past 65 experience significant health benefits and financial stability, highlighting the importance of supportive policies.

13 Feb 2025

Oral vancomycin induces PSC-IBD remission, driving gut microbiome and metabolic shifts

Findings indicate oral vancomycin induces remission in PSC-IBD, with notable microbiota changes and inflammation reduction, reversing after treatment ends.

13 Feb 2025

Vancomycin could offer new therapeutic option for patients with a type of inflammatory bowel disease

An antibiotic used to treat infective diarrhoea could be an effective drug for a type of inflammatory bowel disease, a new study has found.

10 Feb 2025

IBD increases type 1 diabetes risk, revealing a bidirectional link between the two conditions

Researchers discovered that IBD significantly increases the risk of developing T1D, and this association works both ways, independent of genetics and familial factors. The strongest link was seen in ulcerative colitis patients.

19 Sep 2024

Challenges in treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis

Primary sclerosing cholangitis (PSC) is a rare progressive liver disease that damages bile ducts and significantly increases the risk of bile duct cancer, particularly a type called cholangiocarcinoma (CCA).

20 Jun 2024

Genetic discovery reveals key to inflammatory diseases

Researchers discovered that a specific haplotype on chromosome 21 is linked to five inflammatory diseases, offering insights into potential new treatments.

7 Jun 2024

Scientists identify signaling pathway in liver cells linked to fibrosis

A healthy liver filters all the blood in your body, breaks down toxins and digests fats. It produces collagen to repair damaged cells when the liver is injured.

25 Apr 2024

Risk factors for serious inflammatory conditions in IBD patients identified

Investigators at Cedars-Sinai have identified risk factors that make inflammatory bowel disease (IBD) patients susceptible to developing serious conditions in other parts of their bodies.

20 Mar 2024